Transdermal Drug Delivery System Market size was over USD 74.6 billion in 2024 and is estimated to reach USD 296.9 billion by the end of 2037, expanding at a CAGR of 12.2% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the transdermal drug delivery system is evaluated at USD 83.7 billion.
Chronic conditions such as diabetes, cardiovascular diseases, and neurological disorders are on the rise globally, necessitating long-term medication for effective management. For instance, the World Health Organization reported in March 2024 that the number of cases of diabetic neuropathy has more than tripled since 1990, reaching 206 million cases in 2021. The transdermal drug delivery system provides a non-invasive and convenient method for consistent drug administration, eliminating the need for frequent injections and enhancing patient compliance. Their ability to deliver drugs directly through the skin ensures steady therapeutic levels, reducing side effects and improving treatment outcomes, in turn propelling growth for the market.
Additionally, Innovations like microneedles, Iontophoresis, and advanced adhesive patches are transforming the market by enhancing drug adoption and efficiency. Microneedles enable painless, precise drug administration with high loading capacity, as demonstrated by AS Publications (December 2021), where a 41-needle patch loaded 8 μg of medicine and released 80% in one hour. Iontophoresis allows controlled drug penetration using electrical currents, while advanced adhesives improve patch stability and comfort. These advancements enhance reliability and effectiveness, making transdermal systems suitable for diverse applications, driving adoption across therapeutic areas, and propelling market growth.
Growth Drivers
Challenge
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.2% |
|
Base Year Market Size (2024) |
USD 74.6 billion |
|
Forecast Year Market Size (2037) |
USD 296.9 billion |
|
Regional Scope |
|
Technology (Electroporation, Radio Frequency, Iontophoresis, Microporation, Thermal, Mechanical arrays, Ultrasound)
The iontophoresis segment is set to hold more than 22.2% transdermal drug delivery system market share by 2037. This technology enhances drug penetration through the skin using a mild electrical current, facilitating the delivery of both large and small molecules and expanding its applications. A December 2022 study published in the National Library of Medicine demonstrated a 97% swear reduction in four weeks, highlighting its effectiveness. Iotophoresis is non-invasive, offers precise drug release control, and improves treatment outcomes, driving its adoption in treatment outcomes, driving its adoption in therapeutic areas such as pain management and local anesthesia. Thus, propelling the market.
Application (CNS, Pain Management, Cardiovascular, Hormone, Immunological, Metabolic, Gastrointestinal, Infection, Cancer)
Based on application, the pain management segment is slated to hold dominant market share over the forecast period for the transdermal drug delivery system market. The segment’s growth is driven by increasing demand for non-invasive, effective solutions for chronic pain relief. Transdermal patches offer sustained, controlled drug release, ensuring consistent pain management without the need for oral medication or injections. A January 2024 study by Talnia et al. found that 72% of patients experienced great pain relief from analgesic patches. This convenience, coupled with reduced side effects and improved patient compliance, makes transdermal systems a preferred choice for managing conditions like arthritis, neuropathy, and musculoskeletal pain.
Our in-depth analysis of the global market includes the following segments:
|
Technology |
|
|
Application |
|
North America Market Analysis
North America in transdermal drug delivery system market is set to dominate over 43.9% revenue share by 2037. North America, has a strong regulatory framework that supports the approval and adoption of advanced drug delivery systems. The FDA’s initiatives to expedite approvals for innovative drug delivery technologies help foster market growth. Increasing consumer demand for convenient, at-home drug administration options also supports the growth of the transdermal drug delivery system in North America. The ease of use and discreet application are attractive features for patients managing ongoing conditions, thus propelling the market.
As patients seek alternatives to injections, transdermal patches provide a pain-free, convenient, and discreet method for drug administration. This preference for non-invasive treatment options is boosting the demand for market in the U.S. The high cost of healthcare in the country is pushing for more cost-effective treatment solutions. In July 2024, Mylan Technologies Inc. received FDA approval for its estradiol transdermal system (0.0375 mg/day and 0.06 mg/day). Transdermal drug delivery reduces the need for frequent doctor visits and hospitalizations, offering an efficient solution that helps mitigate healthcare costs.
With rising rates of chronic diseases in Canada, there is a growing demand for effective and consistent treatments. In 2021, 45% of Canadians had one chronic illness, and 1 in 12 had three or more, per the Government of Canada in November 2023. Transdermal systems provide an efficient, controlled drug release, improving patient compliance and ensuring better disease management outcomes. Patients in Canada are increasingly opting for non-invasive treatment options due to the discomfort and potential side effects of injections. Transdermal systems, offering pain-free drug delivery systems in Canada, propagating the market.
APAC Market Statistics
The transdermal drug delivery system in APAC region is established to hold lucrative market share over the forecast period i.e. (2025-2037). The growing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and arthritis in the Asia Pacific region is fueling the need for sustainable drug delivery systems. As per the World Heart Federation in December 2024, in the Western Pacific, cardiovascular disease is the leading cause of mortality, contributing to almost 40% of all fatalities. Transdermal patches help manage long-term treatments efficiently, improving patient compliance. Transdermal drug delivery systems are becoming more accessible to a larger population, driving transdermal drug delivery system market growth.
The rapidly aging population in China is driving the demand for chronic disease management and non-invasive drug delivery methods. Transdermal systems offer a convenient and effective solution for managing conditions such as hypertension, diabetes, and pain, increasing their adoption. Additionally, with the rising healthcare awareness among the people in China, patients are more inclined toward non-invasive treatment options like transdermal systems, which provide convenience and reduce discomfort. As per the National Library of Medicine in May 2023, the funding for healthcare in China is steadily rising. In 2021, health spending as a percentage of GDP was 6.5%., thus propelling growth for the transdermal drug delivery system market.
Patients in South Korea are increasingly seeking non-invasive treatments that are easier and more comfortable compared to injections. Transdermal systems offer a pain-free and convenient way to administer drugs, contributing to higher patient satisfaction and increased market demand. Further, the government continues to invest in healthcare modernization, encouraging the development of advanced drug delivery methods. Policies that promote innovation and improve healthcare access are fostering the growth of the market.
Key companies in the transdermal drug delivery systems market are driving innovation through advancements in technologies such as microneedles, iontophoresis, and smart patches. These advancements are revolutionizing how drugs are delivered, offering improved absorption efficiency and better patch adhesion while expanding the range of drugs that can be administered transdermally. A notable example is Adlarity, a transdermal patch for Alzheimer’s disease launched by Corium Inc. in September 202. These innovations are making transdermal systems more effective, versatile, and accessible to patients worldwide These key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?